A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine.

A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine.

Blog Article

More than 170 million individuals worldwide are infected with hepatitis C virus (HCV), and up to an estimated 30% of chronically infected individuals will go on to develop progressive liver USB HDD Docking Stations disease.Despite the recent advances in antiviral treatment of HCV infection, it remains a major public health problem.Thus, development of an effective vaccine is urgently required.In this study, we constructed novel adeno-associated virus (AAV) vectors expressing the full-length NS3 or NS3/4 protein of HCV genotype 1b.

The expression Pain Relief of the NS3 or NS3/4 protein in HepG2 cells was confirmed by western blotting.C57BL/6 mice were intramuscularly immunised with a single injection of AAV vectors, and the resultant immune response was investigated.The AAV2/rh32.33.

NS3/4 vaccine induced stronger humoral and cellular responses than did the AAV2/rh32.33.NS3 vaccine.Our results demonstrate that AAV-based vaccines exhibit considerable potential for the development of an effective anti-HCV vaccine.